EPISODE · Jul 30, 2025 · 7 MIN
Treatment Strategies with ICIs (Efficacy and Safety Data for SC Products)
from Conversations With Cancer Experts About Novel Delivery Options With Checkpoint Inhibitors (ICIs) · host Annenberg Center for Health Sciences
Atezolizumab and nivolumab are both FDA approved as SC products (pembrolizumab pending approval)Overall safety and efficacy of SC ICI products are similar to IV ICI counterpart therapiesPatients receiving SC ICI may experience mild injection site reactionsClinical guidelines (NCCN) recommend
What this episode covers
Atezolizumab and nivolumab are both FDA approved as SC products (pembrolizumab pending approval)Overall safety and efficacy of SC ICI products are similar to IV ICI counterpart therapiesPatients receiving SC ICI may experience mild injection site reactionsClinical guidelines (NCCN) recommend
NOW PLAYING
Treatment Strategies with ICIs (Efficacy and Safety Data for SC Products)
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m